AstraZeneca: collaboration with start-up Immunai on AI

(CercleFinance.com) - Immunai announced Thursday that it has signed a multi-year collaboration agreement with AstraZeneca, which it will help to optimize its clinical trials through AI-based applications.


The Israeli-born start-up, now based in New York, says the cooperation will focus on decision-making, dose selection, understanding mechanisms of action, patient response and biomarker identification.

To this end, AstraZeneca will leverage Immunai's 'IDE' technology for mapping the human immune system, with the aim of maximizing the chances of success of its clinical studies.

Under the terms of the agreement, Immunai will receive $18 million for the initial phase of the program, with an option for AstraZeneca to extend and expand the scope of the collaboration.

Copyright (c) 2024 CercleFinance.com. All rights reserved.